Diverticulitis Disease Market Forecast 2025-2034: Analysing Major Trends, Opportunities, and Growth Drivers

How Are the key drivers contributing to the expansion of the diverticulitis disease market?
Increasing instances of smoking addiction are anticipated to boost the diverticulitis disease market's expansion in the future. Factors such as forceful promotion campaigns, societal approval, stress and the addictive properties of nicotine, are instrumental in the surging prevalence of smoking addiction. Moreover, the undue influence of peer pressure and societal influences on the young generation, alongside the easy access to smoke-related devices like e-cigarettes and vapes, are fuelling the smoking rates. Smoking intensifies the chances of developing diverticular disease by affecting the blood flow to the colon negatively, leading to severe complications, thereby escalating the requirement for medical diagnosis and treatment options. For instance, in July 2022, Statistics Canada, revealed an increase of 5.8% in cigarette production in comparison to June 2021. Also, in June 2022, cigarette sales rose by 1.3% from May 2022, touching a high of 1.4 billion, reiterating that the rising prevalence of smoking addictions would enhance the growth of the diverticulitis disease market. The diverging prevalence of diabetes is correspondingly anticipated to stimulate the diverticulitis disease market's growth. The increasing prevalence of diabetes can be traced back to unhealthy diets rich in processed foods, a sedentary lifestyle, soaring obesity rates, genetic tendencies and an ageing population. People with diabetes are susceptible to complications, like weakened blood vessels making the colon more prone to inflammation and infection, which subsequently leads to a higher demand for treatment options. To cite an instance, in June 2024, NHS England confirmed that in 2023, the count of people identified as prediabetics surged to 3,615,330, recording an 18% rise from 3,065,825 in 2022. Furthermore, a 25% surge was seen amongst individuals under 40 - from 173,166 in 2022 to 216,440 in 2023, reiterating that the mounting prevalence of diabetes stimulates the diverticulitis disease market.

Get Your Diverticulitis Disease Market Report Here:
https://www.thebusinessresearchcompany.com/report/diverticulitis-disease-global-market-report

What growth opportunities are expected to drive the diverticulitis disease market's CAGR through 2034?
The market for diverticulitis disease has seen a swift expansion in recent years, growing at a compound annual growth rate of 10.1% from $1.85 billion in 2024 to $2.04 billion in 2025. Factors contributing to the growth during the historic period include an increase in the aging population, changes in eating habits, a rise in obesity, and advancements in medical imaging technology.

Anticipations indicate a robust expansion in the market size of diverticulitis disease in the upcoming years. The market is predicted to augment to $2.92 billion in 2029, with a compound annual growth rate (CAGR) of 9.4%. The projected escalation in the forecast duration can be credited to factors like colonoscopy and endoscopy, heightened awareness, minimally invasive techniques, and personalized medicine. Key trends during the forecast period encompass preventive strategies, improved diagnostic instruments, partnership care models, and alterations in healthcare policies.

Get Your Free Sample Now - Explore Exclusive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12990&type=smp

How are the latest trends influencing the growth of the diverticulitis disease market?
Leading industry players in the diverticulitis disease market are working towards the creation and approval of novel drugs to maintain their market status. New drug creations could result in more effective diverticulitis treatments, reducing complication risks and enhancing patient results. For example, Seres' microbiota drug for recurrent gut infections received approval from the US-based federal organization, the United States Food and Drug Administration, in April 2023. This drug is specifically formulated to treat repetitive gut infections and to stop adults over 18 years old from getting recurrent Clostridioides difficile (C. diff.) infections. The authorization granted to Vowst came after a clinical trial involving 346 patients with recurrent CDI. This research concluded that patients using Vowst had a considerably decreased likelihood of redeveloping the infection compared to those who were given a placebo. The drug, which is ingested orally, is based on Firmicutes spores microbiota, known to aid a healthy microbiome in resisting C. diff. colonization.

Which growth-oriented segments of the diverticulitis disease market are leading the industry's development?
The diverticulitis disease market covered in this report is segmented -

1) By Type: Uncomplicated, Complicated
2) By Diagnosis: Computed Tomography (CT) Scan, Ultrasound, Urine Test, Blood Test
3) By Treatment: Medications, Surgery, Supportive care, Penicillin Antibiotic, Antibiotics, Dietary Supplements, Intravenous (IV) Fluids
4) By End-User: Specialty Centers, Hospitals, Research centers

Subsegments:
1) By Uncomplicated: Outpatient Treatment, Dietary Management, Antibiotic Therapy
2) By Complicated: Hospitalization, Surgical Intervention, Intravenous Antibiotics, Abscess Drainage

Unlock Exclusive Market Insights - Purchase Your Research Report Now!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12990

What regions are leading the charge in the diverticulitis disease market?
North America was the largest region in the diverticulitis disease market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in diverticulitis disease market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

What companies are at the forefront of innovation in the diverticulitis disease market?
Major companies operating in the diverticulitis disease market are Pfizer Inc., Johnson and Johnson, F. Hoffmann-La Roche AG, Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, Abbott Laboratories, GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Viatris Inc., Teva Pharmaceutical Industries Ltd., Astellas Pharma, Eisai Co. Ltd., Sun Pharmaceutical Industries Ltd., Otsuka Pharmaceutical Company, Cipla Limited, Hikma Pharmaceuticals PLC, Endo Pharmaceuticals, Aspen Pharmacare, Zydus Lifesciences, Lupin Limited, Glenmark Pharmaceuticals, Alkem Laboratories, Torrent Pharmaceuticals Ltd.

Customize Your Report - Get Tailored Market Insights!
https://www.thebusinessresearchcompany.com/sample.aspx?id=12990&type=smp

What Is Covered In The Diverticulitis Disease Global Market Report?

• Market Size Forecast: Examine the diverticulitis disease market size across key regions, countries, product categories, and applications.
• Segmentation Insights: Identify and classify subsegments within the diverticulitis disease market for a structured understanding.
• Key Players Overview: Analyze major players in the diverticulitis disease market, including their market value, share, and competitive positioning.
• Growth Trends Exploration: Assess individual growth patterns and future opportunities in the diverticulitis disease market.
• Segment Contributions: Evaluate how different segments drive overall growth in the diverticulitis disease market.
• Growth Factors: Highlight key drivers and opportunities influencing the expansion of the diverticulitis disease market.
• Industry Challenges: Identify potential risks and obstacles affecting the diverticulitis disease market.
• Competitive Landscape: Review strategic developments in the diverticulitis disease market, including expansions, agreements, and new product launches.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.